This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.
Yescarta is the first CAR T-cell therapy recommended for routine use on the NHS. ... Dr Véronique Walsh, vice president and general manager, Gilead Sciences UK &Ireland said: “This news comes at a time when new hospitals are preparing to deliver CAR
The acquisition will include Tmunity’s ‘armoured’ CAR T technology platform. Kite, a Gilead Company, has agreed to buy Tmunity Therapeutics (Tmunity), a private, clinical-stage biotech focused on cell therapy. ... Tmunity has focused on
a potential for this platform to regulate target antigen-dependent gene expression as a means of improving both the efficacy and safety of first-generation CAR T-cell therapies. ... First-generation autologous CAR T-cell therapies have dramatically
While CAR-T therapy has shown promise in blood cancers, solid tumours present additional challenges. ... Roche’s Genentech and Arsenal Biosciences (ArsenalBio) – a privately held programmable cell therapy company engineering advanced CAR-T therapies
The results strengthen our confidence in CAR T-cell therapies as a truly transformative and paradigm-shifting advance in cancer care, as well as our commitment to continue developing this technology ... The data shows the potential of Kymriah as a cure,
The site in the US will produce CAR T-cell therapies for patients with blood cancers. ... CAR T-cell therapy is unlike other cancer treatments as it is a one-time treatment.
More from news
Approximately 4 fully matching, plus 97 partially matching documents found.
CAR-T is offering an improvement on invasive stem cell therapy, manipulating cells to hunt down and kill cancer cells. ... Multiple myeloma was a major focus, with data presentations on emerging and approved bispecific antibodies and CAR-T therapies
Managing the complexities of current generation CAR-T therapies. While the potential of CAR-T therapies is extraordinary, the complexity and cost of their supply chains jeopardise scalability and long-term ... Today there is research using allogeneic
more as many of the parts don’t mesh together, are fitted at different times and operate across a crowded spectrum. ... We will see faster progress in areas such as CAR-T and gene therapies because these are personalised medicines and the patient is
Historically, both large pharmaceutical and small biotechnology companies have relied on both internal and external sourcing of innovative and promising therapies. ... and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers
impact on the initiation and completion of hundreds of clinical trials involving investigational therapies for many serious diseases. ... Therapy mechanism of action – immunosuppressive therapies and therapies that require complex and prolonged
More from intelligence
Approximately 0 fully matching, plus 29 partially matching documents found.
It is also charged with developing HCP engagement on gene silencing technology and educating on cell therapies such as CAR-T, and the new business unit will provide core expertise in ... He says this will be needed to ensure advanced therapies realise
Ceylad appoints new CFO. Clinical-stage biopharma focused on the development of CAR-T cell therapies has announced that Filippo Petti has been appointed as Chief Financial Officer. ... He said: “Celyad’s differentiated approach to the field of CAR-T
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies. ... With CAR-Ts continuing to take centre stage as a paradigm shift in the treatment of cancer
For example, all CAR-T cell therapies were paused as intensive care unit beds were needed to help COVID-19 patients recover. ... New therapies that minimize hospital visits may have to be prioritized by pharmaceuticals and MedTech companies.
Instead, we carried out in-depth interviews with different types of stakeholders who had considerable experience working on early CAR-T therapies and clinical trials. ... Both of these scenarios were true in the case of the CAR-T treatment.
It’s an exciting time for CAR-T therapy. SA: It’s an integrated, holistic approach. ... This approach can make targeted therapies like CAR-T a reality. A good example at GOSH is in bone marrow transplants.
However, CAR T-cell therapies stop working in some patients and severe toxicity can also occur. ... Other abstracts reported on CAR T-cell therapies for multiple myeloma directed against the B-cell maturation antigen (BCMA).
More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...